Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.38 |
| ▸ | NOS2 | P35228 | 9/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078329 | 1.00 | LMNA (0.38) | LMNASLC6A4NOS2CYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL6078597 | 0.99 | SLC6A4 (0.39) | LMNASLC6A4NOS2CYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL6078592 | 0.99 | SLC6A4 (0.39) | LMNASLC6A4NOS2CYP2D6SLC6A2 | |
| SCHEMBL6078505 | 0.86 | SLC6A4 (0.36) | LMNASLC6A4NOS2CYP2D6SLC6A2 | |
| SCHEMBL6078498 | 0.86 | SLC6A4 (0.36) | LMNASLC6A4NOS2CYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL6077462 | 0.85 | SLC6A4 (0.37) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| Hydrochloric Acid SCHEMBL6077469 | 0.85 | SLC6A4 (0.37) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6079031 | 0.81 | SLC6A4 (0.41) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| Hydrochloric Acid SCHEMBL6078657 | 0.80 | SLC6A4 (0.42) | LMNASLC6A4NOS2CYP2D6SLC6A2 | |
| SCHEMBL6079478 | 0.78 | SLC6A4 (0.50) | LMNASLC6A4NOS2CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | claimed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | claimed |
| EP-1421067-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003011831-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | claimed |
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1421067-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003011831-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS2, NOS1 | LMNA 3092/4885SLC6A4 1543/4885NOS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.